APPOINTMENT OF GRANT THORNTON AS AUDITOR

RNS Number : 0629K

Arecor Therapeutics PLC

27 August 2021

 

Arecor Therapeutics plc

("Arecor", the "Company" or the "Group")

APPOINTMENT OF GRANT THORNTON AS AUDITOR

Cambridge, UK,   27 August 2021:   Arecor Therapeutics plc (AIM: AREC), a globally focused biopharmaceutical group advancing today's therapies to enable healthier lives, today announces that Grant Thornton UK LLP ("Grant Thornton") have been appointed as the Group's auditor, with immediate effect. Lakin Rose Limited has resigned as the auditor of Arecor Limited.

The Board's decision to appoint auditors for the Group was made following a consultation process. Grant Thornton was chosen based on their public company expertise, reputation and experience. Lakin Rose has confirmed that it is not aware of any circumstances connected with its cessation as auditor of Arecor Limited that it considers should be brought to the attention of the Board, creditors or shareholders.

In accordance with section 327(c) of the Corporations Act 2001, a resolution will be tabled at the Company's 2021 Annual General Meeting to ratify the appointment of Grant Thornton as the Group's auditor.

The Board of Directors would like to take this opportunity to thank Lakin Rose UK LLP for their assistance and services to Arecor Limited.

This announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR").

-ENDS-

For more information, please contact:

Arecor Therapeutics plc

www.arecor.com

Dr Sarah Howell, Chief Executive Officer	Tel: [phone] Email: [e-mail]
Susan Lowther, Chief Financial Officer	Tel: [phone] Email: [e-mail]
Mo Noonan, Communications	Tel: [phone] Email: [e-mail]
Panmure Gordon (UK) Limited (NOMAD and Broker)
Freddy Crossley, Emma Earl (Corporate Finance) Rupert Dearden (Corporate Broking)	Tel: [phone]
Consilium Strategic Communications
Chris Gardner, David Daley, Angela Gray	Tel: [phone] Email: [e-mail]

Notes to Editors

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical group transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.

For further details please see our website, www.arecor.com

 

END

 

 

MSCPRMTTMTJTBLB